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612-624, 2010.The Fear of 5-ALA—Is It Warranted?
LETTER:
I read with interest the article by Bi and Laws (2) recently pub-lished in WORLD NEUROSURGERY. The authors give their
perspective on ﬂuorescence-guided resections as a comment on an
article also recently published in WORLD NEUROSURGERY (4). I
could not agree more with the authors’ argument that there is a
good indication that completeness of resection of malignant gli-
omas is of value, provided that it is safe. 5-Aminolevulinic acid
(5-ALA) for ﬂuorescence-guided resections has been developed for
this purpose and is being used in many countries throughout the
world. However, because of regulatory issues, the use of 5-ALA is
still restricted in the United States to centers with scientiﬁc pro-
tocols, and, to my knowledge, Harvard Medical School is not one
of those centers. Nevertheless, the perspective of Bi and Laws (2)
is of interest because it reﬂects what concerns might be derived
from scanning some of the literature if one is not familiar with this
method. Because I am a frequently cited author and quite familiar
with the routine use of 5-ALA, please allow me to give my point of
view, as I ﬁnd some of the authors’ assertions to require some
adjustment.
First, Bi and Laws (2), similar to other authors, resort to the terms
speciﬁcity and sensitivity in conjunction with intraoperative ﬂuores-
cence methods. These measures are inappropriate because they
require random biopsy specimens from healthy brain for their
calculation—strictly speaking, from the brains of healthy in-
dividuals treated with the ﬂuorescence agent. Random biopsy
specimens of normal brain are not feasible, and biopsies of
normal brain have not been performed. The correct measure
would be positive predictive value as an indicator of whether ﬂuo-
rescence correctly shows tumor. In this context, the authors state
that “margins that have been resected because of the presence of
ﬂuorescent signal have also been shown on occasion to lack any
histologic evidence of tumor cells, suggestive of general inﬂam-
matory or reactive changes contribution to presence of ﬂuorescent
marker accumulation” (2). They do not provide a citation for this
statement. Frequently, observations by Utsuki et al. (9) or Panciani
et al. (5) are quoted in this regard. Both groups of investigators
link false-positive ﬂuorescence to peritumoral inﬂammatory cells
and reactive astrocytes, predominantly in recurrences, but not to
normal brain.e30 www.SCIENCEDIRECT.comGiven the millimeter resolution 5-ALA-derived ﬂuorescence has
offered to surgeons, with tissue margins being directly visible and
easily obtainable by biopsy, 5-ALA ﬂuorescenceeguided resections
have been scrutinized more strongly regarding the positive pre-
dictive value than any other technical adjunct available for ﬁnding
tumor intraoperatively (e.g., neuronavigation, intraoperative
magnetic resonance imaging, ultrasound, positron emission
tomographyecomputed tomography with amino acid tracer).
From a publication by our group (8), the authors derive the assertion
that “photobleaching may impair the ﬂuorescence signal.” If they
had read this article more closely, they may have noted that,
depending on illumination intensity, appreciable bleaching in
the intraoperative setting occurs not in seconds or minutes but
after >1 hour of continuous white light illumination. This
bleaching does not normally occur during surgery for malignant
gliomas, and after many years of experience with 5-ALA-derived
tumor porphyrins, I along with other authors do not consider it
an issue at all.
Bi and Laws (2) state that the pharmacokinetic proﬁle of 5-ALA is
suboptimal from the standpoint of efﬁcient delivery of oncologic
care because 5-ALA has to be given at a certain point of time
before surgery and that patients have to be shielded from sunlight
for 48 hours. I fail to understand how the need to administer a
drug at a certain time point before surgery is equivalent to sub-
optimal care. Regarding transient photosensitivity, the recom-
mendation of protection from sunlight is only 24 hours and not 48
(dosing recommendations for Gliolan [Medac, Wedel, Germany])
(6-8). In routine use, this recommendation is not a problem. We
personally take no precautions before surgery and leave patients in
ambient light without direct illumination until the next morning.
This regimen is safe and simple.
Bi and Laws (2) further cite transient allergic reactions, including
generalized edema, and photosensitivity as having been “described
in several case series.” To our knowledge, only a single case of
mucosal edema has been published in 1 article (3), and we have not
encountered any such case in 500 patients closely monitored for
safety during our approval studies (6, 7). We are unaware of any
other case series that report a similar side effect. No other case has
been reported to the European Risk Management plan. I know no
case of any transient allergic reactions to 5-ALA in patients with
brain tumors, and such a reaction is not presented in the article by
Hefti et al. (3), which is cited in this regard.
The authors acknowledge that current results for ﬂuorescence-
guided resections “argue compellingly that maximal resection
improves outcome and maximal visualization, if reliable, improves
resection” (1). I could not agree more.
With this letter, I want to reassure the authors that any fear of 5-
ALA is not justiﬁed provided that 5-ALA is used conscientiously.
Fluorescence-guided resections with 5-ALA are a practical and
simple tool for the neurosurgeon that provide a straightforward
way for visualizing malignant glioma tissue intraoperatively. 5-
ALA-derived porphyrins do not heal malignant gliomas by them-
selves. It is still up to the surgeon to use this information to
perform the best possible resection that is also safe. 5-ALA is only
a small part of the neurooncologic armamentarium in the ongoing
battle against malignant gliomas.81 [5/6]: e27-e36, MAY/JUNE 2014 WORLD NEUROSURGERY
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Open access under CC BY-NC-ND license.Use of Grading Scales in Venous Air Emboli During Neurosurgery
LETTER:
We read with great interest the excellent article by Feigl et al.(2). The authors introduce the Tübingen venous air embo-
lism grading scale, which can be used for grading the clinical
severity of venous air embolism during neurosurgery, and state
that it categorizes the risk of a cardiovascular event depending on
the described parameter changes and visible air bubbles on
transesophageal echocardiography. If this were true, the scale may
be useful, but the authors failed to validate it for that purpose,
meaning it can be used only for descriptive purposes. In itself that
is not a problem, but several comparable scales are in use already
(1, 3-6). All scales differ in the details, causing problems
comparing the data in systematic reviews. New scales should be
introduced sparingly and preferably after validation for either an
outcome or a management decision.WORLD NEUROSURGERY 81 [5/6]: e27-e36, MAY/JUNE 2014Dennis R. Buis and Yen-Mie Lai
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LETTER:
The history of venous sinuses surgery is relatively short. Fromthe time of the ancient Incas, who avoided trephine in the
parasagittal area, until the 20th century, no clear information
about manipulations on venous sinuses exists, perhaps with 2
exceptions. Cushing (3) cited a report by Olof Acrel, who in 1768
operated on a Prussian soldier with a parasagittal mass, presum-
ably a hemangiopericytoma; soon after ﬁnger inspection of the
tumor followed by severe bleeding, the patient passed away in
convulsions. Antoine Louis in 1774 described profuse bleeding
from the superior sagittal sinus (SSS), which appeared in the
course of a parasagittal meningioma removal; in this case the
patient survived (10).
The intracranial venous sinuses were ﬁrst described by Herophilos
of Chalcedon (335e280 BC), but their functional role seems to
have been ﬁrst mentioned by Macewen in 1893 (11). Trollard in
1868 (15) and Labbe in 1883 (8) described venous anastomoses, the
role of which was undervalued before Dandy and Olivecrona.
Compensatory changes of the venous system in intracranial hy-
pertension were ﬁrst described by Blumenau in 1889 (1). Another
Russian scientist, Oppel (13), in 1911 proposed the opening
and enlargement of normally “drowsy” collateral vessels in cases of
venous sinus occlusion. Burdenko in 1927 described the increase
of venous outﬂow velocity in intracranial hypertension (2).
Therefore in the ﬁrst decades of the 20th century, theoretical
and even a practical base of knowledge on the subject appeared.www.WORLDNEUROSURGERY.org e31
